New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
16:24 EDTAGN, VRX, TWTR, SYK, SNN, DSW, DDDOn The Fly: Closing Wrap
Stocks on Wall Street finished lower following a session that began in quiet fashion and remained that way throughout the day. The volume was light, the trading range was tight, and the news flow failed to produce a catalyst that brought buyers into the fray. The S&P 500 touched an all-time high during the session, but was unable to hold onto its narrow gains into the close. Investors will have a busier economic calendar to look forward to tomorrow, which will include the first quarter annualized GDP numbers, weekly jobless claims data, a personal consumption reading, and energy inventory reports. ECONOMIC EVENTS: In the U.S., no major economic data was released. In Europe, a measure of business confidence In the euro area increased to 0.37 in May from 0.28 in April. COMPANY NEWS: Shares of Allergan (AGN) fell $8.90, or 5.39%, to $156.12 after Valeant Pharmaceuticals (VRX) raised the cash portion of its takeover bid by $10 to $58.30, along with 0.83 of a Valeant share and a new contingent value right, or CVR, related to DARPin sales which would provide up to approximately $25.00 per share of additional value. Wells Fargo calculated that, based on Valeant's closing price yesterday, the total new offer for Allergan is around $166 per share, which the firm believes may still be insufficient for Allergan. Following the new bid, which Allergan said it will "carefully review and consider," Valeant shares slid $3.00, or 2.31%, to $126.95. MAJOR MOVERS: Among the notable gainers was Twitter (TWTR), which climbed $3.26, or 10.69%, to $33.77 after Japanese bank Nomura upgraded the stock to Buy from Neutral in a note to investors. Also higher was Stryker (SYK), which rose $2.28, or 2.84%, to $82.64 after Financial Times reported this morning that the company was preparing a takeover bid for its U.K-based rival Smith & Nephew (SNN) and Stryker's CEO reportedly confirmed in an interview that the company was in the early stages of evaluating a potential acquisition of its peer. However, Stryker, at the urging of a British regulator, said it does not intend to make an offer for Smith & Nephew at this time, but reserved the right to make a future bid. Smith & Nephew shares trading in New York advanced $2.71, or 3.37% to $83.05. Among the noteworthy losers was shoe retailer DSW (DSW), which fell $8.90, or 27.37%, to $23.62 and was downgraded at Sterne Agee and Citigroup after its quarter report and yearly profit outlook disappointed. Also lower was 3D Systems (DDD), which slipped $6.20, or 10.95%, to $50.44 after announcing a secondary offering of about 6 million shares. INDEXES: The Dow fell 42.32, or 0.25%, to 16,633.18, the Nasdaq dropped 11.99, or 0.28%, to 4,225.08, and the S&P 500 declined 2.13, or 0.11%, to 1,909.78.
News For AGN;VRX;TWTR;SYK;SNN;DSW;DDD From The Last 14 Days
Check below for free stories on AGN;VRX;TWTR;SYK;SNN;DSW;DDD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
August 20, 2014
17:35 EDTVRX, AGNAllergan said to explore options outside of Salix acquisition, Bloomberg says
Subscribe for More Information
10:53 EDTAGN, VRXAnalysts say Salix takeover would boost Allergan
Subscribe for More Information
09:46 EDTAGN, VRXAllergan merger deal not imminent, CNBC's Faber reports
An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.
09:36 EDTTWTRActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL FOLD TSLA TWTR WHX FB TM NFLX X EOG
07:19 EDTAGNPossible Allergan Salix deal could be 8% accretive in '15-'16, says Wells Fargo
After The Wall Street Journal reported that Allergan (AGN) had approached Salix (SLXP) and other companies about a potential acquisition, Wells Fargo thinks that a largely debt financed purchase of Salix could be 8% accretive for Allergan in 2015-2016, reaching 12% accretion in 2018.
07:07 EDTAGN, VRXSome Valeant shareholders express uncertainty over Allergan deal, Reuters says
Subscribe for More Information
07:04 EDTAGNSalix buyout price could be near $192 per share, says William Blair
William Blair believes a combined Allergan (AGN) and Salix (SLXP) would be very attractive. The firm estimates a potential takeover price for Salix towards the high end of its $176-$192 per share range. Salix rose 16% yesterday to $160.80 after Wall Street Journal reported that Allergan approached the company and at least one other about a takeover.
August 19, 2014
17:14 EDTAGN, VRXOn The Fly: Closing Wrap
Subscribe for More Information
16:52 EDTAGN, VRXAllergan all-cash deal would reduce hostile bid chances, says BMO Capital
Subscribe for More Information
16:00 EDTTWTROptions Update; August 19, 2014eBay
iPath S&P 500 VIX Short-Term Futures down 28c to 27.52. Option volume leaders: AAPL C HD PBR GILD AA NFLX TWTR TSLA EBAY according to Track Data.
14:40 EDTAGNSterne Agee says Allergan could pay up to $190 for Salix and still be accretive
Subscribe for More Information
13:13 EDTVRX, AGNAllergan approached Salix, one other about takeover, WSJ reports
Subscribe for More Information
13:06 EDTAGNSalix jumps 6% to $147.85 after WSJ report of Allergan approach
Subscribe for More Information
13:05 EDTAGNAllergan approached Salix about takeover, WSJ reports
06:10 EDTTWTRTwitter testing highlighting 'favorited' tweets, WSJ reports
Twitter is testing inserting tweets in some users' timelines that have been "favorited" by accounts they follow, an experiment which is receiving mixed reviews, the Wall Street Journal reports. Reference Link
August 18, 2014
16:00 EDTTWTROptions Update; August 18, 2014
Subscribe for More Information
15:59 EDTVRX, AGNAllergan CFO change may suggest strategic deal near, says BMO Capital
BMO Capital believes former Allergan (AGN) CFO Jeff Edwards would not be leaving if a change of control of the company, such as a takeover by Valeant (VRX), were in the future. Rather, BMO thinks Edwards' decision to leave could be a sign that a strategic transaction marking a new chapter in Allergan's growth may be nearing. The firm thinks Allergan is in capable hands with new CFO Jim Hindman and it keeps an Outperform rating on the stock with a $230 price target.
11:57 EDTAGNAllergan CFO departure largely unexpected, says Wells Fargo
Subscribe for More Information
09:02 EDTAGNAllergan names Jim Hindman as CFO, effective immediately
Subscribe for More Information
07:57 EDTAGNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use